In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND – July 6, 2026 -- ...

Japanese biotech drug aims to reverse tooth loss by regrowing teeth. Here's how TRG-035 works, where trials stand and when it ...

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.